Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne (NASDAQ: TECH) will present at two investor conferences in early March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 AM EST and Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM EDT. A live webcast will be available via the company's IR Calendar page.
Bio-Techne (NASDAQ: TECH) announced on Feb 16, 2026 that its Ella benchtop immunoassay platform received CE‑IVD marking and is now available for sale in the European Union. The cartridge-based system delivers biomarker results in under 90 minutes with minimal hands-on time.
The CE‑IVD mark supports Ella's use in clinical trials, in-house test development, and validated clinical applications, while Simple Plex assays remain indicated for research use only.
Bio-Techne (NASDAQ: TECH) announced leadership changes effective March 1, 2026. Dr. Matt McManus will transition from his role as President, Diagnostics and Spatial Biology Segment and will remain with the company temporarily to support a smooth transition. Steve Crouse is appointed President, Diagnostics and Spatial Biology Segment.
Steve Crouse joins from Bio-Techne's Analytical Solutions Division, brings over 20 years of industry experience, and is credited with launching platforms and delivering strong growth during his four-year tenure at Bio-Techne.
Management said McManus played a key role in organizational optimization, including the strategic divestiture of the Exosome business.
Bio-Techne (NASDAQ: TECH) announced a quarterly cash dividend of $0.08 per share for the quarter ended December 31, 2025. The dividend is payable February 27, 2026 to shareholders of record on February 16, 2026. Future dividends will be reviewed quarterly by the board.
The company reported over $1.2 billion in net sales for fiscal 2025 and has approximately 3,100 employees worldwide. The release includes standard forward-looking cautionary language about risks and uncertainties.
Bio-Techne (NASDAQ: TECH) reported second quarter fiscal 2026 revenue of $295.9 million, essentially flat year-over-year, with GAAP EPS of $0.24 and adjusted EPS of $0.46. Adjusted operating margin was 31.1%, up 100 basis points versus prior year, while GAAP operating income rose 15% to $54.5 million.
Management cited productivity initiatives and the Exosome Diagnostics divestiture as drivers of margin improvement, with continued strength in large pharma and growth in China/APAC. A conference call and replay are available February 4, 2026.
Bio-Techne (NASDAQ: TECH) launched Cultrex Synthetic Hydrogel on February 2, 2026, a fully defined synthetic extracellular matrix (ECM) for 3D stem cell and organoid culture. The product aims to reduce lot-to-lot variability, support scalable workflows, and align organoid research with regulatory and translational initiatives.
The hydrogel is presented as a synthetic alternative to animal-component matrices to improve reproducibility, traceability, and adoption of new approach methodologies (NAMs) in drug screening, toxicology, and personalized medicine.
Bio-Techne (NASDAQ: TECH) launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform on January 28, 2026, enabling femtogram-level detection of neurological biomarkers including NFL, GFAP, pTau 217, and Amyloid β (aa1-42).
The assays deliver improved analytical sensitivity, automated microfluidic workflow with under three-hour runtime, and build on Ella's extensive publication record to support earlier detection and reproducible quantification in neuroscience research. Assays are for Research Use Only.
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, February 4, 2026 at 8:00 a.m. CST to review second quarter fiscal 2026 financial results.
Live access: dial 1-800-579-2543 or 1-785-424-1789 (international) using Conference ID TECHQ2, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available from 11:00 a.m. CST on Feb 4, 2026 through 11:00 p.m. CST on Mar 4, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160826.
Bio-Techne (NASDAQ: TECH) announced that Kim Kelderman, President and CEO, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PST. A live webcast will be available via the company's Investor Relations Calendar page.
Investors can access the presentation through the IR Calendar on Bio-Techne's investor relations website.
Bio-Techne (NASDAQ: TECH) announced a strategic collaboration with the Wyss Center Geneva on Dec 11, 2025 to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens. The project aims to extend Bio-Techne's multiomic spatial biology capabilities from 2D into intact 3D samples, enabling high-resolution multiomic analysis in thicker sections.
The collaboration targets automation to reduce manual complexity, accelerate drug discovery and diagnostic development, and support New Approach Methodologies (NAMs) such as organoids and AI-driven predictive modeling to potentially reduce animal testing. Executives from both organizations cited the partnership as a step to broaden accessibility of spatial biology tools for preclinical research.